Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content]

Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.